OBJECTIVE： To observe the efficacy and safety of Sanjiao fuzheng mixture combined with concurrent chemoradiotherapy of paclitaxel and nedaplatin in the treatment of local advanced non-small cell lung cancer （NSCLC）. METHODS： A total of 68 patients with local advanced NSCLC selected from our hospital during Jan. 2015 to Jan. 2017 were divided into control group and observation group according to random number table， with 34 cases in each group. Control group was given Paclitaxel injection 135 mg/m2 intravenously， d1+Nedaplatin for injection 75 mg/m2 intravenously， d3， 21 d as a treatment course， for 2 courses；routine fractionated intensity modulated radiation therapy， 2 Gy each time， 5 times a week， 60-70 Gy in total； given 2 cycles of primary chemotherapy continuously after radiotherapy. Observation group was additionally given Sanjiao fuzheng mixture 250 mL/d， divided into 3 times， till the end of treatment， on the basis of control group. Clinical efficacies were observed in 2 groups. The levels of nutritional indexes （BMI， PAB， ALB， Hb） and tumor markers （SCC-Ag， CEA， TK1， CYFRA21-10） before and after treatment were observed. The occurrence of ADR were recorded. RESULTS： There was no statistical significance in the total effective rate between 2 groups （observation group 82.35％ vs. control group 73.53％） （P＞0.05）. After treatment， the levels of BMI， PAB， ALB and Hb in 2 groups were significantly lower than before treatment， but the observation group was significantly higher than the control group. The levels of SCC-Ag， CEA， TK1 and CYFRA21-1 in 2 groups were significantly lower than before treatment， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. The incidence of Ⅲ-Ⅳ degree aleucocytosis，Ⅰ-Ⅱ degree hemoglobin reduction and thrombocytopenia in observation group were significantly lower than control group， with statistical significance （P＜0.05）. CONCLUSIONS： The efficacy of Sanjiao fuzheng mixture combined with concurrent chemoradiotherapy of paclitaxel and nedaplatin is similar to that of concurrent chemoradiotherapy of paclitaxel and nedaplatin for local advanced NSCLC， which can improve nutritional status significantly， and reduce the incidence of ADR.